Management of Menorrhagia Associated With Chemotherapy-Induced Thrombocytopenia in Women With Hematologic Malignancy

Jill S. Bates, Pharm.D., M.S.; Larry W. Buie, Pharm.D.; C. Brock Woodis, Pharm.D.


Pharmacotherapy. 2011;31(11):1092-1110. 

In This Article

Future Studies

Oral contraceptives have not been proven to be effective for the management of menorrhagia or breakthrough bleeding in women with thrombocytopenia, although they are used. Current studies are attempting to define the place in therapy of oral contraceptives among women with heavy menstrual bleeding and thrombocytopenia. The Eunice Kennedy Shriver National Institute of Child Health and Human Development is sponsoring a study that is enrolling patients with aplastic anemia who are aged 15–55 years and have active uterine bleeding.[74] Patients receive either an oral contraceptive tablet twice/day or placebo. In addition, all patients will receive platelet transfusions to maintain platelet counts greater than 20 × 10 3/mm 3. After 1 week, those continuing to have bleeding will continue twicedaily oral contraceptive, and those with cessation of bleeding will receive continuous oral contraceptive once/day. Treatments will be compared for the percentage of patients not bleeding at 7 and 14 days.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.